Roth Capital Starts Flex Pharma (FLKS) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
JMP Securities Starts Flex Pharma (FLKS) at Market Outperform
February 23, 2015 7:34 AM ESTJMP Securities initiated coverage on Flex Pharma (NASDAQ: FLKS) with a Market Outperform rating and a price target of $30.00.
For an analyst ratings summary and ratings history on Flex Pharma click here. For more ratings news on Flex Pharma click here.
Shares of Flex Pharma closed at $14.71 yesterday.
... MoreCantor Fitzgerald Starts Flex Pharma (FLKS) at Buy
February 23, 2015 7:34 AM ESTCantor Fitzgerald initiated coverage on Flex Pharma (NASDAQ: FLKS) with a Buy rating and a price target of $22.00.
For an analyst ratings summary and ratings history on Flex Pharma click here. For more ratings news on Flex Pharma click here.
Shares of Flex Pharma closed at $14.71 yesterday.
... MoreJefferies Starts Flex Pharma (FLKS) at Buy
February 23, 2015 7:15 AM ESTJefferies initiates coverage on Flex Pharma (NASDAQ: FLKS) with a Buy rating and a price target of $25.00.
Analyst Ryan Martins comments, "FLKS' proprietary formulation of transient receptor potential (TRP) ion channel activators is well positioned to address muscle cramps and other neuromuscular... More
Piper Jaffray Starts Flex Pharma (FLKS) at Overweight; Sees ~70% Upside
February 23, 2015 6:50 AM ESTPiper Jaffray initiates coverage on recent IPO Flex Pharma (NASDAQ: FLKS) with a Overweight rating and a price target of $25.00.
Analyst Joshua Schimmer commented, "We are initiating coverage of Flex Pharma with an OW rating and $25 PT, representing ~70% upside from... More
